Leerink Partners analyst Marc Goodman has maintained their bullish stance on ACIU stock, giving a Buy rating yesterday.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Marc Goodman has given his Buy rating due to a combination of factors surrounding AC Immune SA’s recent developments. The company has reported promising interim results from its Phase 2 VacSYn trial for the ACI-7104 vaccine, which targets alpha-synuclein, a protein associated with Parkinson’s disease. This vaccine has shown a significant increase in anti-alpha-synuclein antibodies, indicating potential efficacy in treating the disease.
Furthermore, the safety profile of the vaccine is favorable, with only mild side effects reported. Goodman is optimistic about the upcoming biomarker data expected later this year, which could further validate the vaccine’s potential and support the decision to advance to the next phase of trials. This combination of positive trial results and the anticipated future data contributes to the Buy rating for AC Immune SA.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $16.00 price target.